DATA BOOK 2022 English 03/04/2022
The DATA BOOK organizes the statistics on pharmaceutical industries both in Japan and around the world.
We would be grateful if this is utilized as a tool for promotion of understanding about pharmaceutical industries, making medical care policies, or planning strategies for pharmaceutical industries.
There were some errors in the content on page 12, 35, and 36, which should be corrected as follows:
Errata: Page 12 (on June 30, 2022)
A-2-3 Comparison of Pharmaceutical Sales between Domestic and Foreign Companies (Japan)
Fiscal Year 2019
Domestic / Ratio Error 90.2 Correction 89.8
Foreign / Ratio Error 9.8 Correction 10.2
Total / Total Sales (JPY mil.) Error 13,199,398 Correction 11,432,500
Errata: Page 35 and 36 (on August 18, 2022)
A-4-2 International Trade of Pharmaceutical Products by Partner Countries (Japan)
Corrected the Imports/Exports values and shares for each country in 2020.
Corrected the Imports/Exports values and shares for each country in 2020.
*The materials posted on the website have been revised. We apologize for this.
Secondary Use of Data in DATABOOK
Full Report
English
Japanese
Table List of DATABOOK
Download page by page.
A.Pharmaceutical Industry Outlook
A1.Pharmaceutical Manufacturers / Employment
- A1-1:Number of Pharmaceutical Manufacturers (Japan) (17KB)
- A1-2:Number of Pharmaceutical Manufacturers by Number of Employees (Japan) (20KB)
- A1-3:Employment in the Pharmaceutical Industry (Japan) (21KB)
- A1-4:Employment in the Pharmaceutical Industry (Europe) (17KB)
- A1-5:M&A in Pharmaceutical Industry (Japan) (1.4MB)
- A1-6:M&A in Pharmaceutical Industry (Worldwide) (1.4MB)
A2.Pharmaceutical Market
- A2-1:Pharmaceutical Market -Manufacturers Sales- (Japan) (18KB)
- A2-2:Sales of Pharmaceutical Manufacturers by Capital Scale (Japan) (17KB)
- A2-3:Comparison of Pharmaceutical Sales between Domestic and Foreign Companies (Japan) (16KB)
- A2-4:Concentration on Pharmaceutical Sales to Leading Companies (Japan) (17KB)
- A2-5:Ethical Drug Market (Japan) (15KB)
- A2-6:Ethical Drug Sales -20 Leader Companies- (Japan) (17KB)
- A2-7:Pharmaceutical Market (Worldwide) (24KB)
- A2-8:Concentration on Pharmaceutical Sales to Leading Companies (Worldwide) (22KB)
A3.Financial Results / Value-Added
- A3-1:Financial Results of JPMA Member Companies (24KB)
- A3-2:Financial Results of the Leading Pharmaceutical Manufacturers (Japan) (19KB)
- A3-3:Financial Results of the Leading Pharmaceutical Manufacturers (Worldwide) (21KB)
- A3-4:Oversea Sales of Pharmaceuticals (Japan / USA / Europe) (34KB)
- A3-5:Comparison of Profitability by company for research-based industries (Worldwide) (25KB)
- A3-6:Comparison of Profitability by industry sectors for research-based industries (Japan) (17KB)
- A3-7:Value-Added Ratio of Industrial Sectors (Japan) (19KB)
A4.Exports and Imports (Pharmaceutical Products / Technology)
- A4-1:International Trade of Pharmaceutical Products (Japan) (16KB)
- A4-2:International Trade of Pharmaceutical Products by Partner Countries (Japan) (27KB)
- A4-3:Export / Import of Major Countries (Worldwide) (32KB)
- A4-4:Exports / Imports of Pharmaceutical Products by Partner Country (Worldwide) (22KB)
- A4-5:Technology Exports and Imports in the Pharmaceutical Industry (Japan) (17KB)
A5.Overseas Business of Japanese Companies
- A5-1:Overseas Business of Japanese Pharmaceutical Companies (Japan) (15KB)
- A5-2:Overseas Business of Japanese Pharmaceutical Companies by countries (Japan) (19KB)
- A5-3:Overseas Sales and Number of Employees (JPMA Member Companies) (16KB)
- A5-4:Number of Overseas Bases (JPMA Member Companies) (15KB)
- A5-5:Overseas Bases by Countries (JPMA Member Companies) (36KB)
A6.Pharmaceutical Production
A7.Research and Development
- A7-1:R&D Expenditures of the Pharmaceutical Industry (Japan) (16KB)
- A7-2:R&D Expenditures of Leading Pharmaceutical Manufacturers (Japan) (25KB)
- A7-3:R&D Expenditures of Leading Pharmaceutical Manufacturers (Worldwide) (27KB)
- A7-4:Trends of R&D Expenditures and Profits as Sales Ratio (Japan) (35KB)
- A7-5:Trends of R&D Expenditures and Profits as Sales Ratio (USA) (36KB)
- A7-6:R&D Expenditures as a Percentage of Sales by Industry (Japan) (20KB)
- A7-7:R&D Expenditures by Industry and Type (Japan) (16KB)
- A7-8:R&D Expenditures by Developmental Stage (USA) (19KB)
- A7-9:Success Rate of Developing New Drugs (Japan) (22KB)
A8.Patents
- A8-1:Number of Patents for Drugs in Japan (16KB)
- A8-2:Number of Published Patent Applications for Drugs by Company in Japan (20KB)
- A8-3:Number of Published Patent Applications for Bio-Technology in Japan by Applicant's Nationality (15KB)
- A8-4:Published PCT Applications by Pharmaceutical Company (20KB)
- A8-5:Number of Published PCT Applications for Biopharmaceuticals by Applicant's Nationality (15KB)
A9.Pharmaceutical Affairs Government
- A9-1:Trends in Notification of Clinical Trials (Japan) (17KB)
- A9-2:Development Times for New Molecular Entities (Japan) (15KB)
- A9-3:Approval Times for New Drugs (Japan) (16KB)
- A9-4:Number of New Molecular Entities Approved (Japan) (16KB)
- A9-5:Number of New Molecular Entities Approved (company specific) (Japan) (16KB)
- A9-6:Number of Pharmaceutical Approvals (Japan) (16KB)
- A9-7:Number of Pharmaceuticals Included in the NHI Price List (Japan) (15KB)
B.Statistics on Health
B1.Life Expectancy / Vital Statistics
B2.Health Care Expenditures
- B2-1:National Health Care Expenditures (Japan) (17KB)
- B2-2:National Health Care Expenditures (Worldwide) (24KB)
- B2-3:National Health Care Expenditures and Share by Source of Revenues (Japan) (17KB)
- B2-4:National Health Care Expenditures and Share by Source of Revenues (USA) (19KB)
- B2-5:Proportion of National Treasury Expenses in National Health Care Expenditures (Japan) (16KB)
- B2-6:Proportion of National Treasury Expenses in National Health Care Expenditures (USA) (17KB)
- B2-7:Social Benefit by Category (Japan) (20KB)